A comprehensive solution

With broad scale coverage, a DNA+TM sequence produced on the Helix clinical laboratory platform can be used throughout a person’s life—enabling healthcare professionals, researchers, and the individual to gain a lifetime of insights.

In-house expertise

Helix has dedicated bioinformatics, laboratory, and clinical affairs teams to facilitate the delivery of actionable genetic insights at scale.

CLIA/CAP sequencing lab

Helix’s Exome+ assay—which covers the whole exome plus 300,000 additional informative regions—is used in our high throughput, CLIA-certified, and CAP-accredited laboratory.

Sequence once, query often

Helix sequences and securely stores Exome+ data on behalf of each participant. Access the data you need, and with the participants' consent, you can come back for more when you're ready.

Advancing population genomics

CASE STUDY

Compelling headline about the Healthy Nevada Project

Short description of the Healthy Nevada Project lorem ipsum 2 lines.

Learn more

POWERED BY HELIX

Compelling headline about the Helix projects

Short description about Helix projects lorem ipsum 2 lines.

Learn more

RESEARCH

Compelling headline about the research at Helix

Short description of the Helix research lorem ipsum 2 lines.

Learn more

Privacy is our number one priority.

We won’t share data without permission. As founding members of the Future of Privacy
Forum, we pledge to uphold the highest standards of bioethics and maintain rigorous policies and procedures to keep individual’s data safe and secure.

Learn how we protect data

*A panel-grade assay

Helix's proprietary Exome+ assay is described as "panel-grade" because we've designed it to deliver a ~100% call rate across every base within a predefined set of representative panels.

White papers and more

Partner with us

Helix provides the infrastructure and services to help you carry out population-scale genomic screening and research initiatives, including one of the world's largest CLIA / CAP next-generation sequencing labs. Together, we can drive earlier identification of at-risk individuals and accelerate innovative research efforts.

Learn more

*Panel-grade: defined as a ~100% call rate across every base within clinically relevant panels (offering equivalent or superior quality to clinical panels in the market).